<DOC>
	<DOCNO>NCT01128452</DOCNO>
	<brief_summary>This study 4-week , randomize , double-blind , parallel-group , placebo-controlled monotherapy study patient treatment-resistant major depression . After confirmation treatment-resistance prospective treatment period citalopram , patient treat either EVT 101 daily placebo 28 consecutive day .</brief_summary>
	<brief_title>Safety Efficacy EVT 101 Treatment-Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Major Depressive Disorder Current episode major depression benefit least 1 3 adequate treatment regimen Has score &gt; /= 18 HamD17 Pregnant breastfeed woman Evidence agerelated cognitive decline mild dementia At imminent risk commit suicide Has exception major depression , serious medical neurological illness , include seizure disorder , stroke , dementia , Parkinson disease Has establish diagnosis bipolar disorder , hypomania , schizoaffective disorder , major depression psychotic feature schizophrenia Has substance alcohol abuse dependence disorder ( except nicotine caffeine ) 1 year screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Treatment-Resistant Depression</keyword>
</DOC>